EyePoint Pharmaceuticals (vorher: PSIVIDA) startet durch !! (Seite 1169)

[Radegast10]

Guten Morgen


ASX/MEDIA RELEASE 21 May 2004 University of Pittsburgh Collaboration Loading DNA Vaccines into BioSiliconTM Global nanotechnology company pSivida Limited (ASX: PSD), is pleased to announce that its UK operating subsidiary pSiMedica has entered into a collaborative agreement with the University of Pittsburgh to examine the use of BioSiliconTM as a potential delivery platform for its proprietary DNA vaccine technology. Delivery and expression of DNA to cells has been challenging for many companies particularly for vaccine applications. The collaboration with the University of Pittsburgh will explore the use of BioSilicon™ in binding and protecting DNA during vaccine therapy in model systems. pSiMedica has developed the technology to load and release DNA from BioSilicon™ matrices resulting in effective production of immunogen (the antigen for which the DNA codes). The ability to load and protect DNA during vaccine regimens is vital to the production of DNA vaccine products The University of Pittsburgh, through the laboratories of Professor Ted Ross, is ideally suited to collaborate with pSiMedica as they have extensive experience in DNA vaccines to a variety of viral diseases. Professor Ross has extensive experience with vaccine development in HIV/AIDS. The University of Pittsburgh has a strong history in vaccine development having in 1955, together with Jonas Salk, developed the first successful vaccine for polio. Mr Gavin Rezos said, “This new relationship will build on the previous work of the Company in the valuable DNA vaccine area. We are very pleased to be working with the University of Pittsburgh and Professor Ross given their noted experience in this area. This new collaboration also demonstrates the Company’s increasing profile in the United States and is the second collaboration of the Company in Pennsylvania this year, following on from the NanoHorizons collaboration announced in February.” Professor Ross said “The new collaboration has the potential to significantly move the field of DNA vaccination forward by providing a new platform for the delivery of DNA vaccines for a variety of diseases, including cancer, HIV/AIDS, tuberculosis, SARS, as well as biodefense agents such as Ebola, Anthrax, and Smallpox. The inability to manufacture and deliver vaccines to people will, in the end, be a major impediment to the successful development and commercialization of these products. The combination of the clinical-based vaccine research at the University of Pittsburgh and the BioSilicon™ technology and expertise of pSiMedica will be combined to effectively develop vaccines for human use.” -ENDS- Released by: Josh Mann Investor Relations pSivida Limited Tel: + 61 8 9226 5099 [e-mail]
NOTES TO EDITORS: pSivida Limited pSivida is an Australian-based biotechnology company committed to the biomedical applications of nano-technology and which has as its core focus the development and commercialisation of nano-structured porous silicon (BioSilicon™ in biocompatible and biodegradable forms for use in healthcare through its UK subsidiary pSiMedica Limited, and in conjunction with QinetiQ plc (formerly the UK Government owned Defence Evaluation Research Agency, DERA). As a true ‘platform technology’, BioSilicon™ has multiple potential applications across the high growth healthcare sector, including controlled drug delivery, brachytherapy, tissue engineering and orthopaedics. pSivida is listed on the Australian Stock Exchange (ASX Code: PSD). pSivida is also listed in Germany on the Frankfurt Stock Exchange on XETRA system, as well as Berlin, Munich and Stuttgart, ( German Symbol: PSI. Securities Code (WKN) 358705). For more information visit www.psivida.com.au pSiMedica Limited (UK) pSiMedica has identified a biocompatible and biodegradable form of silicon (BioSilicon™. The technology is based on applying a modified form of the silicon chip (porosified or nano-structured silicon) in a variety of healthcare applications, ranging from controlled drug delivery, brachytherapy, tissue engineering and orthopaedics to clinical diagnostics. pSiMedica’s market strength lies in its international management and science team, including former Chairman of SmithKline & French Research, Dr Roger Brimblecombe, former PepTech CEO Dr Roger Aston, and, the world eminent scientist and the inventor of BioSilicon™, Professor Leigh Canham. The Company has access to cutting edge research and development facilities of QinetiQ plc, the largest science and technology company in Europe. pSiMedica owns the worldwide intellectual property rights to nano-structured porous silicon, known as BioSilicon™, for use in or on humans and is dedicated to realising the potential of porous silicon products in areas such as controlled drug delivery, diagnostics and orthopaedics. For more information visit www.psimedica.co.uk University of Pittsburgh Founded in 1787 the University has 12,000 employees, including 3,800 faculty members, serves more than 34,000 students through the programs of 18 undergraduate, graduate and professional schools. In 1955 the University together with Jonas Salk, developed the first successful vaccine for polio. An extensive testing of the vaccine followed in the US and parts of Canada. The scope of the trials was unprecedented in medical history at that time. In 1984, the world`s first double transplant operation was performed by University of Pittsburgh surgeons. The University’s transplant programs in conjunction with the hospitals of UPMC Medical Center are internationally renowned, performing more types of organ transplants than at any other institution. In 2002, The University of Pittsburgh ranked in the top ten in the US for attracting research funding from the National Institutes of Health (NIH) with a total of $425 million.


Gruss R.

[Michael@]

Es hat ja auch schon einer mit 7,00 EUR gekauft,
habe mich aber dann über die 10,00 gefreut...

es gibt eben noch pioniere... die uns zeigen wohin der zug fährt...

Aber toothstone, 100 EUR miese ist etwas zu wenig finde ich...

[toothstone]

530 st, mit 100 Euronen Miesen mit einem blauen auge davongekommen.

[rattelu]

Abwarten, dass kommt noch! Da hat einer auf Xetra wohl sein Kauflimit vergessen,oder er brauchte noch ein paar Verluste für seine Steuererklärung.

[marc22]

wenn ich meine nur zu dem kurs verkaufen könnte.

aber das ist wohl zu schön um wahr zu werden.

[covino02]

uiuiuiui- was ist denn da auf xetra passiert

[OGgun]

@ Radegast
Vielen Dank,Perfekt die Site

[Radegast10]

PSD) PSIVIDA LIMITED
ORDINARY FULLY PAID
21 May 2004 16:29 Delayed | Live Quote
Last Price +/- % Open High Volume
$1.1200 $0.0100 0.9% 1.1200 1.1400 965,896
Bid Ask # Bid # Ask Low Value
1.1100 1.1200 1 4 1.1000 1,078,815

[Radegast10]

hallo Leute!

versuch mal hiermit!

http://www.tradingroom.com.au/apps/qt/quote.ac?code=PSD§ion=…

gruss R.

[OGgun]

Guten Morgen @ all
Kann mir bitte jemand mal einen Link geben wo
ich die Schlusskurse in Aussiland finde
Vielen Dank und einen erfolgreichen Handelstag